University of Tennessee, Knoxville

TRACE: Tennessee Research and Creative
Exchange
Chancellor’s Honors Program Projects

Supervised Undergraduate Student Research
and Creative Work

Spring 4-2002

p53's Role in Tumor Suppression
Robert Daniel Thurman
University of Tennessee - Knoxville

Follow this and additional works at: https://trace.tennessee.edu/utk_chanhonoproj

Recommended Citation
Thurman, Robert Daniel, "p53's Role in Tumor Suppression" (2002). Chancellor’s Honors Program
Projects.
https://trace.tennessee.edu/utk_chanhonoproj/606

This is brought to you for free and open access by the Supervised Undergraduate Student Research and Creative
Work at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Chancellor’s
Honors Program Projects by an authorized administrator of TRACE: Tennessee Research and Creative Exchange.
For more information, please contact trace@utk.edu.

AppendixD-

UNIVERSITY HONORS PROGRAM
SENIOR PROJECT - APPROVAL

Name:

__ ~Q~__ J~~c~~ _____________________________ _

College:

ALt..2_"':'-~~~~~';'__

Fa cui ty

Men tor:

PROJECT

TITLE:

Department:

__ Je.LQ._M@.f'.cw~

__~icl.Q%-~ ___________ _

___________________________ _

___p5_3.:...~_gQ.Y.LJ..il.. __~L. __ ~Y;.Ilfl.~~~~i:if.l __

I have reviewed this completed senior honors thesis with this student and certify
that it is a project commensurate with honors level undergraduate research in this
field.
Signed:

-~-~~;L.

::::....<:...-.~_::::_:r;:___

Date:
Comments (Optional):

27

_ ________ ,

Faculty

Mentor

p53's Role in Tumor Suppression

Abstract
The p53 protein is involved in many varied cellular processes including DNA
repair, recombination, differentiation, and senescence (Bates and Vousden, 1999). This
review concerns with the tumor suppression functions of the protein through cell arrest
and apoptosis. The most well known function of p53 is its transcriptional activity. The
protein has a sequence-specific DNA binding domain which mediates this process. This
binding causes the transactivation of genes like Bax, p21, and MDM2 which are
important players in the tumor suppression function of the protein. This review will deal
with how p53 is recruited, the role of p53 in causing cell cycle arrest and apoptosis, and
how the decision of which pathway to follow is made. Some historical and background
information will be provided and the discussion will be concluded with some possible
uses of p53 in the clinical treatment of cancer. Most ofthe experiments cited in this
paper used either mice or human tumor cell lines, which were deficient in wild type p53,
in the hopes that some common mammalian model may emerge that can provide insights
into the role p53 plays in tumor suppression.
Introduction

In recent study by the CDC and the National Centers for Health Statistics, it was
estimated that 541,859 deaths in America were contributed to malignant neoplasms
(National Centers for Health Statistics, 2001). This means that approximately twentythree percent of all recorded deaths were the result of cancer, making it the number two
killer of Americans. It is no wonder why so much energy has been focused toward how

cancer is caused and how we can treat this killer. An emerging player in the study of
cancer is a protein known as p53. This protein has gotten much attention because it has
been estimated that between twenty and fifty percent off all cancer cases have a mutated
p53 gene. The protein that this gene codes for has many functions within the cell and its
properties could make it a very effective player in cancer treatment.

I. History of p53
The p53 protein was first identified as a protein that precipitated out of cells along
with the SV40 large T antigen (Maxwell et ai, 1995). It was a phosphoprotein with a
molecular weight of 53,000. The protein was initially though to have oncogenic
properties because it could immortalize cells in culture and could cooperate with the
activated ras oncogene to transform cells in culture (Maxwell et ai, 1999). It was also
initially found that over expression of the p53 protein enhanced the transformed
phenotype of tumor cells. Because of these early findings, it was thought that p53 would
actually cause cancer. Upon further investigation, however, it was found that all of the
pS3 discovered had actually been mutated versions of the wild type pS3 tumor
suppressor. The structure ofp53 consists ofthree domains (Fig. 3.). The N-terminal
domain is responsible for the transactivation of p53 by other proteins (Choisy-Rossi et ai,
1998). The central domain is responsible for the sequence specific DNA binding ofp53.
The C-terminal domain is responsible for the oligomerization ofp53 and the possible
negative regulation ofp53. The theories of the role of the C-terminal domain are
discussed below.

----

--------~.---.

II. Background

To fully understand the effects of p53 on the cell and its functions we must
discuss the processes that serve as the backdrop to the protein's function. The p53
protein helps regulate cycles that are continuously occuning within the cell. Completely
comprehending p53's effects requires understanding of the cell cycle, the apoptotic
pathway, and how p53 behaves when there is no cellular stress.
A. CeU Cycle
Since p53 is a known tumor suppresser, one must realize how these tumors begin
to form. Tumors form when cells lose the ability to control the normal process of cellular
growth and division. This regulated growth and division cycle is most commonly known
as the cell cycle (Fig. 1.). The cell cycle consists of four stages. The mitotic, or M, stage
is the point in the cell cycle in which the cell divides. The following phase is one of two
phases in the cell cycle in which the cell's organelles and cytoplasm grow. This first
growth phase, G1, is the longest of the four phases and can be extended by arresting the
cell in senescence. Muscle and neuronal cells can be placed in senescence permanently.
The replication or synthesis of a new copy ofthe cells DNA characterizes the next stage,
synthesis, or S phase. The second growth phase, G2, is responsible for the growth and
division of organellular components of the cell. Another mitotic division and another cell
cycle follow this final stage. (Voet and Voel, 1995)
The above process needs tight regulation to avoid over-replication and tumor
formation. The progression from Gl to S and G2 to M provide the checkpoints for most
ofthe cell cycle's progression (Bird, 1996). This regulation comes in the form of cyclindependent kinases (CDK). The CDK are composed of the catalytic kinase unit and a

cyelin cofactor and are only active when the cofactor is present and the kinase is in its
proper phosphorylation state (Voet and Voet, 1995). The prototypical example COK and
its activity is the cyelin B-p34 complex. Once the COK is active, it will phosphorylate
and activate specific proteins which will propel the cell cyele forward. This paper will be
concerned mostly with the Gl to S transition. Cyclin E-cdk2 complex and the cyelin 01,
2, oc3-cdk4,

5, or 6 complexes are responsible for regulation of this progression (Bird,

1996). These complexes phosphorylate Retinoblastoma protein (Rb) which will in twn
release E2F. E2F is a transcription factor that transcribes proteins such as dihydrofolate
reductase, thymidine kinase, and ONA polymerase a, which are required to begin S
phase (Bird, 1996). Release ofE2F along with activation other proteins via
phosphorylation will cause the cell to progress into S phase. p53' s activity at this
checkpoint will be discussed below in greater detail.

B. Apoptosis
A key function ofp53 is apoptosis (Fig. 2.). Some general information about the
apoptotic pathway should be mentioned to help us understand what role p53 has in this
process. Apoptosis seems to rely on proteins known as caspases (Hengartner, 2000).
The proteolytic activity of these caspases is critical to the initiation of apoptosis.
Caspases are present in the cell in inactivated forms called procaspases (Hengartner,
2000). These procaspases are activated in one of two ways. The first activation pathway
occurs via a death receptor (Bates and Vousden, 1999). The death receptor molecule is a
receptor protein that resides on the condemned cell's membrane. Forthe receptor to
become activated, it must bind to an extracellular molecule that is released when death
needs to be promoted. The cell death receptor complex has a proteolytic activity, which

causes a procaspase 8 molecule to be cleaved and thus activated (Hengartner, 2000). The
second method of activating caspases relies on signals from the mitochondria. Cellular
signals, including those of p53, cause the mitochondria to loose membrane potential and
release cytochrome c into the cytoplasm (Bates and Vousden, 1999; Hengartner, 2000).
The free cytochrome c binds to a different caspase molecule, procaspase 9 and its
cofactor, Apaf-l, to form the activated caspase 9 (Soengas et al, 1999). Several of the
activated caspase 9 molecules come together possibly along with other proteins to form
an apoptosome (Hengartner, 2000). Caspase g and the apoptosome are able to cleave
themselves and other procaspases like caspase 3, 6, and 7 (Hengartner, 2000). This
results in a caspase cascade which enhances the apoptotic pathway.
These caspases are the primary proteins involved in proteolytic cleavage of
substrates in apoptosis. The cleavage of specific proteins by caspases can either activate
cell destruction enzymes like CAD and P AK-2, or destroy existing proteins like Lamin,
fodrin, or gel solin (Hengartner, 2001). CAD is a DNase which will clip DNA in to
thousands of fragments. PAK-2 causes the blebbing seen in dying cells. Cleavage of
Lamin results in the shrinking and budding of the nucleus. Fodrin and gelsolin are
cytoskeletal elements whose destruction leads to the cells loss of shape. These effects
along with others are the main causes of cell death and are characteristic of the apoptosis
pathway.
C. p53 in Nonnal/Healthy Cells

This report deals with the function of p53 in cells that are under some kind of
stress, but what happens to p53 in normal cells. In a healthy cell p53 is present in the
nucleus of the cell in very small amounts. The p53 protein is bound by MOM2, a protein

transcribed by p53 in a negative feedback loop. MDM2 is an E3 ligase which means that

it can attach ubiquitin molecules to proteins, including p53. This ubiquitination results in
the expulsion ofthe complex from the nucleus to the cytoplasm and flags the protein for
degradation via proteosome. Therefore, the activity ofMDM2 keeps the cellular
concentrations ofp53 low in the cell. (Vousden, 2000) Although most of the time p53
must be shuttled outside of the nucleus by MDM2, recent studies have shown that p53
can also be degraded inside of the nucleus. This nuclear degradation is proposed to have
a faster effect and tighter control of the active p53. Nuclear degradation would act as a
"quick off switch" (Shirangi et aI, 2001)

m.

Recruitment of p53
In normal cells, it has been shown that p53 is removed from the nucleus and

degraded by proteosomes as a result of the interaction with MDM2. Therefore, in order
for p53 to become activated and arrest or destroy the cell, the interaction with the MDM2
protein must be abolished. There are several cellular pathways involved in this process.
These pathways are what signals cell damage and recruits the activities of p53 by
stabilizing p53's presence in the nucleus.

A. Phosphorylation
MDM2 binds to p53 at the N-terminal region of the p53 protein (Bai and
Merchant 2001). If the p53 protein is phosphorylated at or near the N-terminal end, then
this could cause steric interference or a conformational change that would not allow
MDM2 to bind to p53 and would therefore limit the removal ofp53 from the nucleus
(Rich et ai, 2000). The lack ofMDM2 interaction would result in more p53 in the
nucleus and an increase in the transcriptional activity of the protein.

One specific example of this pathway occurs when there is a double strand break
in the DNA. When a double strand break occurs in the DNA, a protein called Ataxia
Telaniectasia Mutated (AIM) binds to the break (Rich et ai, 2000). Binding to the DNA
activates the protein kinase activity of AIM, which phosphorylates p53 preferentially at
Serine 15 in the amino terminal end. This phosphorylation changes p53's confonnation
and inhibits the interaction ofp53 with MDM2 (Rich et ai, 2000). Phosphorylation,
then, results in the loss of interaction of p53 with MDM2 and an upregulation of p53
activity (Fig. 4.).

B. RemovalofMDM2
Another way the MDM2/p53 interaction can be inhibited is through the removal
of MDM2 by other proteins. The best example of this type of interaction is the ARF
protein. The ARF protein is able to bind to MDM2 which disrupts the MDM2/p53
interaction by sequestering and degrading MDM2 (Bai and Merchant, 2001). ARF binds
to MDM2 in a region separate from the p53 binding domain, therefore, the ARF protein
does not directly disrupt the interaction between p53 and MDM2 (Bai and Merchant
2001). ARF is activated by the over expression of oncogenes such as Myc, Ras, and
E2FI (Vousden 2000). These oncogenes serve as signals to the cell that there is
abnormal proliferation and will result in the activation of ARF and eventually p53.
ZBP-89 is another protein that inhibits the actions ofMDM2 on p53. ZBP-89,
however, binds to p53 instead ofMDM2 and does not inhibit the binding ofp53 to
MDM2. The effect of ZBP-89 is that although MDM2 is still bound to p53, it can no
longer transport it out of the nucleus or target it for degradation. It is thought that the
ZBP-89 protein can either sterically mask the degradation sites on p53 or recruit p300 to

acetylate p53 (Bai and Merchant 2001). Acetylation by p300 may act in a similar manner
as phosphorylation in protein stabilization. In either case p53 remains in the nucleus
where it can act to arrest or destroy the cell. (Bai and Merchant, 2001)

C. p53 Binding

Once the p53 is present and stable in the nucleus, the protein must bind to the
specific sequences of its target genes. Two thoughts exist on how p53 accomplishes this
task. The classical view of this process is that the C-terminal end of the protein regulates
the binding ofp53 to DNA target sequences. The C-terminal end negatively controls
DNA binding, but this inhibition can be alleviated by acetylation, phosphorylation, or
protease cleavage. Once modified the p53 can then bind to DNA and begin the
transcription process by recruiting the transcription machinery of the cell. (Espinosa and
Emerson, 2001)
The most recent view states that p53 has intrinsic chromatin binding activity and
the C-terminal domain of p53 actually serves as a regulatory element. This model
suggests that the p53 protein binds to DNA in its chromatin complex without the need for
modification (Espinosa and Emerson, 2001). Recently it has been shown that p53
actually binds to a coactivator CBP/p300 (Livengood et al, 2002). Interruption of this
binding leads to reduced p53 transcriptional activity. Once p53 binds to the DNA, it
recruits p300 to acetylate the nucleosomes immediately up and downstream ofp53. This
results in the spreading of the open conformation of DNA to the TAT A box where
transcription can begin in earnest. In either case, the presence of p53 results in the

transcription of genes needed in the regulation of the cell cycle. (Espinosa and Emerson,
2001)
IV. Functions of p53 in Tumor Suppression

As previously discussed p53 can undertake activities such as DNA repair,
recombination, and differentiation. The main body of research, however, has been in the
tumor suppressive function of the protein. Once p53 is active and present in the nucleus,
it can function to suppress tumor growth in one of two ways (Fig. 5.). The protein can
stop uncontrolled cell growth by arresting the cell cycle thus allowing for DNA repair, or
it can trigger the cell to undergo apoptosis. Either pathway prohibits the cell from
endangering the organism further.

A. Arrest
One main function of the tumor suppression activities of p53 is the arrest of the
cell so that damaged DNA is not synthesized. The transcription of the gene p21 is the
primary method by which p53 stops the cell cycle when slight DNA damage is present.
The p21 protein is a potent eyclin dependent kinase inhibitor. Expression of the p21
protein results in the cessation of the cell cycle between the Gland S phases. The
arresting capabilities of p21 are so efficient that the protein has been implicated in the
terminal differentiation of cell lines such as muscle and gut epithelium (Bird, 1996; EIDeiry, 1998). Upon the p53 mediated transcription ofp21, the protein interacts with the
cyclin dependent kinase (Cdk) complex in order to inhibit the Cdk's activity. By
inactivating the Cdk, the E2F 1 transcription factor remains bound to the Retinoblastoma
(Rb) protein. If the Rb protein is not phosphorylated and thus inactivated by the Cdk,
then the cell cycle cannot progress into S phase.

There are several possible ways in which p21 can inhibit the Cdk complex. The
p21 protein possesses tyrosine phosphatase activity which can remove phosphate groups
from the Cdk molecule (Bird, 1996). The Cdk molecule must be phosphorylated at
conserved residues to become active (Chellappan et ai, 1998). Without the correct
phosphorylization status, the Cdk molecule will be inactive and progression through the
cell cycle would cease. The p21 protein could possibly dephosphorylate the Cdk at
specific sites that would reduce its activity and thus arrest the cell cycle.
In a similar manner, p21 could interrupt the interaction of Cdk to the Cdkactivating kinase, an enzyme responsible for the phosphorylation and resulting activation
of the Cdk. Experiments have shown that p21 blocks the phosphorylation ofCdk by the
Cdk-activating kinase (Aprelikova et ai, 1995). Because there was no direct interaction
found between p21 and the activator, it is believed that p21 covers the sites of the Cdk
molecule that need to be phosphorylated (Aprelikova et ai, 1995). As described above,
unless the Cdk is in its correct phosphorylization state, then it will remain inactive.
The p21 protein could also interact with the Cdk complex by interfering with the
cyclin binding to the Cdk molecule. By altering the interaction of the cyclin and the Cdk
molecule, the Cdk molecule will remain inactive. This hypothesis is supported by the
fact that the cyclin-Cdk inhibitory domain ofp21 contains distinct cyclin- and Cdkinteracting regions (EI-Deiry 1998). A similar molecule, p27, has features similar to
those of p21. The Cdk complex with p27 bound has an altered kinase formation resulting
in steric interference of ATP binding in the active site (EI-Deiry 1998).
A second way that p21 can arrest the cell cycle of the cell is by its association
with Proliferating Cell Nuclear Antigen (PCNA). PCNA associates with DNA

polymerase I) to increase the polymerase's processivity (Voet and Voet, 1995). PCNA
forms a trimeric ring around the DNA molecule in order to keep the polymerase attached
and continue replication (Voet and Voet, 1995). The crystal structure ofp21-PCNADNA suggests that the p21 protein masks the sites on PCNA that allow for binding to
proteins such as DNA polymerase I) (El-Deiry, 1998). This activity ofp21 will cause the
cell to stop the replication of its DNA, and keep the cell in the Gl phase of the cell cycle.
Whether by interacting with the Cdk complex or with the PCNA, p21 arrests the
cell cycle in the Gl phase. This arrest will allow the cell to repair or replace the damaged
DNA so that the mutation rate due to damage is minimized. This p53-mediated pathway
can only work effectively when DNA damage is minimal. More extensive damage
results in more drastic measures.
B. Death

If the DNA damage is extensive enough, p53 will cause the cell to undergo
progranuned cell death. The p53 protein can utilize two pathways to sensitize the cell to
apoptosis. The first pathway utilizes the mitochondria and its constituents. As discussed
above, cytochrome c is an important component in beginning the caspase cascade. The
second pathway involves the upregulation of death receptors which also results in a
caspase cascade. In either case, genes transcribed by p53 will cause the cell to undergo
programmed cell death.
i. Mitochondrial Interactions

The first pathway that will be considered is the mitochondrial mechanism which
results in apoptosis. The mitochondria are well known for being the powerhouses of the
cell. Besides providing the ATP the cells uses for energy, the mitochondria houses

proteins whose release results in rapid cell death. Proteins such as cytochrome c,
SmacIDIABLO, AIF, and an array ofprocaspases are located within the mitochondria
(Hengartner,2000). Release of these proteins from the mitochondria will likely result in
the apoptotic destruction of the cell (Fig. 2.). p53 transcribes genes whose activities
result in the release of some of these proteins.
The most effective and thus deadly of the proteins which the mitochondria carry
is the cytochrome c molecule. Cytochrome c usually functions as an electron carrier on
the outer surface of the inner mitochondrial membrane (Voet and Voet, 1995). Once
cytochrome is released into the cytosol, however, it complexes with procaspase 9 and
Apaf-l to form an active caspase (Soengas et ai, 1999). Several of these active caspase
molecules will converge to form a larger structure called an apoptosome whose activity
results in the cleavage of key cellular components to induce apoptosis (Hengartner,
2000). The ability to shuttle cytochrome c out of the mitochondria, as is evident, is a
crucial step in triggering the apoptotic pathway.
SrnacIDIABLO and AIF are two other proteins housed in the mitochondria that
have a direct effect in the apoptotic activities of the cell. SmacIDIABLO is a protein
whose activity inhibits the activities of the inhibitors of apoptosis proteins (IAP), a
powerful inhibitor of activated caspases (Hengartner, 2000). Random, unintentional
activation of a caspase could quickly activate other caspases to begin the caspase cascade.
IAPs protect against this possibility. When the mitochondria is disturbed enough, it will
release the SrnacIDIABLO protein to ensure the IAP will now inhibit the apoptotic
cascade. The AlF is another protein whose presence results in apoptosis, yet in a caspase
independent pathway that has yet to be fully described (Hengartner, 2000).

The activity ofpS3 is involved in the release of these mitochondrial proteins into
the cytosol. pS3 alters the functions of the cell membrane through several of its target
genes. Noxa, Bax, p53AIPI and p53DINPI are targets ofp53 whose activities disrupt
the membrane permeability and lead to the release of some or all of the proteins
mentioned above.

a. Bcl-2 Family
The pS3 protein transcribes two genes, Bax and Noxa, who are members ofa
family of proteins called Bcl-2 proteins. The Bcl-2 family derives its name from B-cell
lymphoma, a condition in which the gene is involved. This family is composed of three
subcategories: the antiapoptotic group land the proapoptotic groups 2 and 3 (Fig. 6.).
The Bcl-2 family is related by their homologies over four possible sequences. The Bcl-2
family of proteins are the molecules that are primarily responsible for the integrity of the
mitochondrial membrane. (Hengartner, 2000)
The antiapoptotic members of group I are responsible for suppressing the
mitochondrial disruption signals that the other two groups convey. Members of this
group, including Bcl-2 and Bcl-XL, possess sequence homology within all four BH
domains. The group I family also possesses a hydrophobic transmembrane domain on
the C-terminal end of the protein which anchors the protein into the surface of the
mitochondria. (Hengartner, 2000)
The proapoptotic members of group 2, including Bax and Bak, possess
homologies in the BHI-BH3 domains (Hengartner, 2000). This group is missing the
BH4 homology, but it does have a transmembrane domain on their C-terminal ends. This
allows the group 2 members to insert themselves into the mitochondrial membrane once

they are activated. The group 3 members have homology only in the BH3 domain, so are
often referred to as BH3 domain only molecules. Proteins such as Noxa, Bid, and Bik are
members of this group (Oda E, et ai, 2000). The group 2 and 3 members are able to exist
both in the cytosol and in association with the mitochondria's membrane.
The way these proteins interact with each other determines the fate of the
mitochondria and also the cell. It has been found that the ratio between the antiapoptotic
and multidomain proapoptotic members helps determine the susceptibility of the cell to
the death signal (Cheng et ai, 2001). A greater concentration of group 1 members will
inhibit the release of cytochrome c and increase the likelihood of survival for the cell. A
greater concentration of group 2 members, however, will result in the loss of cytochrome
c and other possible proteins which will initiate the caspase cascade.
The proapoptotic group 2 members are believed to be located in the cytosol in an
inactive form. Upon interaction with the BH3 domain only members, the group 2
members become activated and localize to the mitochondria (Fig. 7.). Once in the
mitochondria, the group 2 members homooligomerize and act in a variety of ways to
disrupt the mitochondrial membrane. The group 1 members limit the activational
properties of the BH3 domain only members by sequestering them in mitochondrial
complexes. If the antiapoptotic members bind all of the BH3 members, then the
activation of the proapoptotic members cannot occur. (Cheng et a1, 2001)
Several theories exist on how the Bcl-2 family members disrupt the mitochondrial
membrane (Fig. 8.). The first hypothesis asserts Bcl-2 family members are able to form
pores in the mitochondria's membrane which can allow the transport of cytochrome c
into the cytoplasm. Two main lines of evidence support this belief. The Bcl-Xr. is

structurally similar to the pore forming subunit of the diphtheria toxin. In vitro, BcI-2
family members can insert themselves in synthetic lipid bilayers, oligomerize, and form
channels which allow the passage of particles. These channels could, conceivably, allow
the passage of cytochrome c and activate the caspase cascade. (Hengartner, 2000)
Another theory suggests that the Bcl-2 family of proteins could interact with other
proteins already present on the surface of the mitochondrial membrane. It has been
shown that the Bcl-2 family is able to associate with other proteins. These interactions
could interact with membrane channel proteins already present in the outer membrane of
the mitochondria. This could alter the conformation and allow the release of the
cytochrome c protein. The activity of the Voltage Dependent Anion Channel (VDAC) is
shown to be regulated by Bcl-2 family members. The pore of the VDAC is too small to
allow for the cytochrome c to pass, so the channel will have to undergo significant
conformational changes in order for this event to occur. (Hengartner, 2000)
The final theory suggests that the Bcl-2 family members cause the rupture of the
cell membrane through the loss of mitochondrial membrane potential. This could happen
via the intrinsic pore forming abilities and the association with other proteins discussed
above. Channel formation by the Bcl-2 family members could result in the alteration of
the mitochondria physiology possibly through the ion exchange or oxidative
phosphorylation perturbations. This loss of homeostasis would result in organelle
swelling and rupture of the outer membrane. The rupture would cause the release of
cytochrome c and other mitochondrial proapoptotic proteins mentioned above. The
interaction with the VDAC protein could also result in the loss of membrane potential.
The VDAC is a subunit of the permeability transition pore (PIP), whose opening results

in loss of membrane potential and organellar swelling. Opening of the PTP corresponds
to a release of cytochrome c and rupture of the organelle's membrane. In either case, the
contents of the mitochondria are released and apoptosis shortly follows. (Hengartner,
2000)
The p53 targets ofBax and Noxa are key players in the regulation of
mitochondria membrane integrity. Both Bax and Noxa are proapoptotic proteins whose
expression leads to a higher probability ofapoptosis occurring. Not all ofp53's target
genes are members of the Bel-2 family, however, and apoptosis could occur by other
mechanisms.

b. Non Bcl-2 genes
Bax and Noxa are not the only targets of p53 whose expression result in increased
apoptotic activity. The protein p53DINPI contains a p53 binding sequence and is
expressed in response to an upregulation ofp53 (Okamura et al, 2001). The role of this
protein is to promote phosphorylation of p53 by an unknown serine kinase.
Phosphorylation ofp53 at Serine 46 results in the increased affinity ofp53 to the
p53AIPI promoter (Okamura et al, 2001; Oda K. et ai, 2001). Once p53AIPI is
transcribed, the protein is localized to the mitochondria where it disrupts the
mitochondrial membrane potential (Oda K. et ai, 2001). Similar to the actions of the Bel2 group, the loss of membrane potential results in the rupture ofthe mitochondria's outer
membrane and loss of cytochrome c. Thep53 protein, itself, can affect the membrane
potential of the mitochondria by localizing to the mitochondria and disrupting the
membrane potential through an as yet undetermined mechanism (Marchenko et al, 2000).
ii. Death Receptors

Other than the mitochondrial pathway, p53 can induce apoptosis by upregulating
the transcription of cell death receptors and their adaptor molecules. A correlation has
been shown between the activity of p53 and the expression of death receptors such as
DRS and Fas (Bates and Vousden, 1999). Although no p53 promoter sites have been
found on these receptor's genes, a positive correlation is present and p53' s activity is
thought to be involved in some way. Active p53 can also transcribe other proteins
needed by the death receptors to link them to the caspases. Pidd is one of these adaptor
molecules that p53 can transcribe (Lin et aL 2000).
Death receptors are proteins that activate a caspase molecule upon binding of a
ligand (Fig. 2.). This may seem relatively simple, but quite a bit of coordination goes
into this process. First the death receptor must translocate itself from the Golgi to the cell
membrane (Bennett et ai, 1998). Experiments have shown that p53 helps in this
translocation process. Once the receptor is on the surface of the cell it can bind to a death
ligand such as TRAIL. Binding of the ligand causes the association of several death
receptors and recruitment of an adaptor molecule such as Pidd or Fadd. These adaptor
molecules have domains which associate with both the death receptor and the caspase
(Lin et ai, 2000). Caspase cleavage will result from this process. How cleavage occurs is
unclear, yet it is hypothesized that procaspases have slight intrinsic protease activity
(Hengartner, 2000). When several procaspases are in close proximity (as in the case of
the death receptors), spontaneous cleavage will occur and the caspase cascade will begin.
Whether by transcribing genes or interacting with the cell itself, p53s presence
greatly enhances the cells predisposition to undergo apoptosis. By utilizing the two
distinct pathways of mitochondrial interactions and death receptors, p53 allows the cell

more than one way to destroy itself. This ensures that the cell will undergo apoptosis if
such drastic measures are needed.
So p53 acts as a tumor suppressor by arresting the cell cycle if slight DNA
damage is present and causing apoptosis when DNA damage is more severe. These
mechanisms help to guarantee the fidelity of the genetic code as the cell is replicated.
These activities limit the frequency of tumor development and enhance the overall
survival ofthe organism.
Decision Between Arrest and Death
It has been shown that p53 has two responses to cell damage: arrest of the cell
cycle and programmed cell death. The question remains, however, how does the cell
choose which response will be initiated? Do other cellular factors control arrest or death,
or can the protein make the decision itself? Two models have been proposed to explain
the possible decision making process.
A. Dumb Model
One model suggests that p53 reacts the same way each time it is activated by
cellular stress (Vousden, 2000). In this "dumb" model, the protein will transcribe the
same genes whenever it is activated. The decision will rely on the cell to make the
decision between arrest and death. Signals for arrest and programmed cell death are sent
from p53 and the cell must either inhibit the death signal to arrest the cell cycle without
killing the cell, or amplify the death signal above threshold to trigger apoptosis (Vousden,
2000). The anti-apoptotic members of the BcI-2 family, Bcl-XL and Bcl-2, have been
shown to suppress the apoptotic activity of Noxa (Cheng et ai, 2001). Similar antiapoptotic proteins or survival factors could bring the apoptotic signal below threshold and

save the cell from death. The opposite scenario could be that other p53 independent
pathways could produce their own signals which would amplify p53s signals, thus
triggering the death pathway (Vousden, 2000). An example of this pathway involved p53
and another tumor suppressor E2F-1. Neither of these proteins acting alone can induce
apoptosis efficiently, but when pS3 is active and E2F-l is deregulated, apoptosis occurs
(Bates and Vousden, 1999). The singular activation of all p53 targets along with the
reliance on other cellular signals characterizes the dumb model.

B. Smart Model
The second model used to describe the decision making process involves p53
being expressed in various concentrations and various active states. In this model, p53,
itself, is responsible for affecting which outcome is produced. One theory suggests that
the arresting genes have promoters that bind p53 with greater affinity than the apoptotic
promoters. This would mean that enough active p53 would have to be present to bind
first to the arresting genes and then still have enough free protein left over to bind to the
apoptotic genes. If the cell was damaged or stressed to a small degree, then the p53
protein would only be present in small amounts, thus transcribing arresting genes which
would allow time for the removal of the stress. If too much stress is present, then the
levels of p53 would be greater so that it would bind to both the arresting and the
apoptotic genes. This may be the case since it has been noted that cells going through the
apoptotic pathway have also been arrested. (Vousden, 2000)
Besides the amount ofp53 produced, the state of the protein can also help
determine which genes would be produced. One apoptotic target gene of p53, p53AlPl,
is dependent on the phosphorylation status ofp53. IfpS3 is phosphorylated at Serine 46,

then the levels ofp53AIPI are greatly increased (Oda K. et ai, 2000). p53 can also be
modified by acetylation, sumoylation, and glycosylation (Vousden, 2000). These
modifications can lead to alterations in the conformation of p53 causing a change in the
affinities for certain promoters. These alterations in p53 could possibly switch the
transcriptional activity from arrest to apoptosis, or vise versa.
Clinical Implications
Due to the role of p53 in cellular arrest and destruction and the high frequency of
p53 mutations in human cancers, the loss of p53 may be a key component in the
formation of tumors. Loss of the DNA damage inducible checkpoint, for example, could
lead to tumor formation due to the propagation of damaged DNA through the replication
cycle. Replicating damaged DNA results in higher mutation rates for the replicated cell.
Loss of the p53' s apoptotic activities would allow cells which are growing without
regulation to continue to grow uncontrollably and without a way to check that growth. In
either case, the loss of p53 could quickly lead to the loss of genomic integrity and the
eventual formation of tumors. (Wallace-Brodeur and Lowe, 1999)
Since p53 mutations are so closely linked with cancer, scientists have been trying
to find away to use p53's functional status as a tool to direct their prognosis and
treatment. The nature of p53 suggests that tumor cells with mutant p53 should be
inherently more aggressive than tumors bearing the wild-type protein. Physicians have
begun trying to find a correlation between the status of p5 3 and the prognosis of the
patient. Not all tumor types show this a correlation, and some cancers are even treated
more effectively when a mutant p53 is present. The status of p53, for example, provides
the best indicator for the recurrence in breast cancer. (Wallace-Brodeur and Lowe, 1999)

Physicians are also able to use p53 as a prognostic indicator because of its ability
to make tumors resistant to chemotherapies. Most chemotherapeutical drugs use
cytotoxic agents that directly or indirectly damage DNA. These drugs use the cells own
apoptotic systems to trigger cell death in cells that have been treated. If there is loss of
p53's apoptotic activity, then the cell may not react nearly as effectively in beginning
apoptosis. p53 is linked to drug resistance in several tumor types including; nonHodgkin's lymphoma, acute myeloid leukemia, myelodysplastic syndrome, and chronic
lymphocytic leukemia. Loss of p53 in these tumor types is generally associated with
poor prognosis and shorter survival times. This correlation is not universal. One cell
line, p21 deficient HeT 116 colon carcinoma cells, actually shows increased sensitivity
due to mutated p53. No matter what sign p53 mutations may give, the hope is that
physicians and scientists may rely of p53 to give some prognostic information to the
patient's condition. (Wallace-Brodeur and Lowe, 1999)
Another, more ambitious, thought is that p53 status could be used to determine
the course of treatment forthe patient. For example, if a patient is harboring a p53
mutant, then insertion of a functional p53 gene or protein could confer sensitivity to the
cytotoxic drugs used in chemotherapy. Another option is to use drugs that circumvent
the p53 pathway in order to cause the tumor cells to die. An example of this type of
treatment involves using microtubule inhibitors to kill the cell. A third option involved
using the body's own immune system to destroy the cell. By creating antibodies that
recognize mutant p53, the immune cells in the body can target the tumor genes and
destroy them. Success has been approach has been seen in mouse dendritic cells. The
final option involves using a virus to replicate and destroy cells that are deficient in p53

activity. The ONYX-DI5 virus inserts itself into all the cells in the region, but is only
able to replicate in cells lacking p53 activity. ONYX-DI5's replicative cycle causes lysis
in the tumor cells while leaving the healthy cells unaffected. All of these new therapies
hold promise for the effective treatment of human cancers. (Wallace-Brodeur and Lowe,
1999)
Summary and Conclusions

As discussed above, p53 is a transcription factor whose activity suppresses tumor
growth and formation. This tumor suppression occurs through arrest or apoptotic
pathways. The p21 protein is the major effector for the arrest pathway, while the
apoptotic pathway is activated by the p53-mediated transcription of various genes
involved in mitochondrial interactions and cell death receptors. The decision between
arrest and death is made by the activity status of the protein or the activities of other
proteins in the cell. In either case, the cell is protected against the replication of
dysfunctional DNA and the possibility of tumor formation.
As the high mutation rates of p53 in various human cancers suggest, p53 plays a
major part in tumor suppression. By studying p53, scientists will be better able to
understand how our own bodies fight to prevent harmful mutations that could deregulate
the growth of the cell. The study ofp53 will provide more specialized and effective ways
to treat human cancers. While a cure for cancer is still decades away, studies of p53 and
other tumor suppressors will provide valuable information which will lay the
groundwork for better cancer therapies and possibly a cure.

Fig. 1. Cell Cycle (Voet and Voet, 1995)

Fig. 2. Apoptotic pathways (Hengartner, 2000)

Fig. 3. Structure ofp53 (Choisy-Rossi et ai, 1998)
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